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Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by development of autoantibodies that bind platelet membrane glyr
colproteins and active complement activation, leading to 
rapid clearance of the plateletrantibody complex via the 
hemophagocytic system mainly in the spleen. In adults, 
initial treatment with steroids and/or intravenous imr
munoglobulins can induce a response. However, upon 
withdrawal or tapering of steroids the majority relapse.1 
Splenectomy represents a strategic curative procer
dure for the majority of patients with chronic ITP who 
fail to respond or relapse after primary medical treatr
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BACKGROUND: idiopathic thrombocytopenic purpura (itp) in adults has a chronic course and may necessitate 
splenectomy. the current study was undertaken to study the systemic thromboembolic complications of laparo-
scopic splenectomy (ls) versus open splenectomy (os) in patients with itp at two large referral hospitals.
PATIENTS AND METHODS: We conducted a retrospective analysis of 49 patients who underwent splenectomy 
(21 ls and 28 os) for primary/relapsing refractory itp between June 1995 and november 2004. clinically 
and/or radiologically confirmed deep venous thrombosis (dVt) and/or pulmonary embolism (pe) were assessed 
within 2 weeks before and after splenectomy. none had prophylactic anticoagulants immediately after surgery. 
follow up of those who developed complications continued for at least 2 additional years to assess for contribut-
ing factors that may have been masked at the time of occurrence.
RESULTS : two (9.5%) ls group had acute pe within 5 days of ls and their platelet count reached 500×103/µl 
within 4 days and 1000×103/µl within 7 days after surgery. three conversions to os occurred; none had Vte. 
dVt occurred in 3 patients (10.7%) in the os group; none were life threatening. there were no deaths.
CONCLUSION: life-threatening venous thromboembolic events are serious complications after ls and os for 
itp patients if prophylactic anticoagulants are not administered. patients at risk are those who both have an 
exponential rise of the platelet count, although factors other than the platelet count may be contributing in os. 
postsplenectomy, itp should be considered as a thrombophilic condition and studies of additional measures to 
prevent such events are warranted.
ment.2 Although laparoscopic splenectomy (LS) has 
been introduced relatively recently (in 1990s), its applir
cation has witnessed a larger scale use at many centers 
due to its advantage of being “endoscopic’, less traumatic, 
and less disfiguring with a relatively short stay; it is also 
supposed to be associated with fewer complications,3r
5 including life threatening events and periroperative 
mortality.6 Its application is ideal when the splenic size 
is small or nonpathologic as in cases of ITP. When spler
nectomy is done via an open approach and in clonal disr
orders, precautions for deep vein thrombosis (DVT) 
prophylaxis are usually applied due to the heightened 
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risk of venous thromboembolism (VTE) that is asr
sociated with the underlying disease. However, due 
to the bleeding tendency with ITP and the relatively 
short duration of the procedure when the laparoscopic 
approach is taken, no prophylactic anticoagulants are 
usually administered.7,8 Due to an absence of prospecr
tive studies discussing the need for thromboprophyr
laxis in such a situation in this target population of 
patients, universal guidelines for VTE prophylaxis in 
ITP are lacking although they are sorely needed.9 
Thromboembolic complications, including DVT, 
pulmonary embolism, portal vein thrombosis, inferior 
vena caval thrombosis and mesenteric vein thrombosis 
may occur in an average of 10% of patients with hemar
tological diseases undergoing splenectomy. However, 
the incidence may range between 1% to 75%, dependr
ing on the underlying hematological disease and the 
clinical situation as well as the occurrence of postopr
erative complications like infections and prolonged 
recumbency.8,10
The advantages of the laparoscopic approach in 
ITP patients that have been reported are shorter operr
ation time, decreased estimated blood loss, decreased 
length of hospital stay and less chance of conversion 
to open splenectomy (OS) than in any patients with 
any other diagnosis.11 Therefore, LS has become the 
procedure of choice for patients with medically refracr
tory ITP requiring removal of the spleen. Surgeons 
who are seeking to undertake, or who currently are 
practicing this procedure, should be aware that it is 
considered an advanced laparoscopic procedure and 
is associated with a significant learning curve that has 
yet to be defined.12 Much of the pertinent data pubr
lished in the surgical journals are focused mainly on 
the effectiveness in curing ITP, hospital stay, cost efr
fectiveness or postoperative infectious complications 
or bleeding and/or thrombosis.13r15 Few studies have 
comprehensively reported systemic thromboembolic 
complications, like DVT and or pulmonary embolism 
without detailed mention of factors contributing to 
such events or suggestions for preventive measures.13 
However, most of the available studies suffer from a 
small sample size (less than 20 patients), lack longr
term follow up and sometimes include other hemar
tological disorders with unclear thromboprophylaxis 
strategy.5 The current study was undertaken to study 
the systemic thromboembolic complications of LS in 
comparison to OS done for patients with ITP who did 
not received anticoagulant thromboprophylaxis at Ain 
Shams University Hospitals, Cairo, Egypt and North 
West Armed Forces Hospitals, Saudi Arabia with a 
minimum follow up of 2 years (range 2r4 years).
PATIENTS AND METHODS
The study was a retrospective analysis of 49 consecur
tive patients with a preoperative diagnosis of ITP 
who underwent splenectomy (21 laparoscopic and 28 
open) by two separate teams at Ain Shams University 
Hospital, Cairo, Egypt and North West Armed Forces 
Hospital, Tabuk, Saudi Arabia, from June 1995 to 
November 2004. Those who developed systemic VTE 
were further followed for at least 2 years postrsplenecr
tomy. The majority of patients had been referred from 
teaching hospitals and private clinics. Splenic or portal 
vein thrombosis was not systematically or prospectively 
sought in our study.
All patients fulfilled the ITP definition proposed in 
guidelines,16 namely: (1) the presence of thrombocytor
penia before treatment; (2) either a normal or increased 
number of megakaryocytes in the bone marrow; (3) no 
history of recent ingestion of a drug known to induce 
thrombocytopenia; (4) no congestive splenomegaly; 
(5) no known history of secondary immune thromr
bocytopenia, sepsis, or intravascular consumption. 
Initial work up of patients before starting steroids and 
before splenectomy followed the American Society of 
Hematology Guidelines.17 Special attention was made 
to the normal/or increased number of megakaryocytes 
with defective budding and to the absence of any other 
intrinsic bone marrow abnormalities. Review of bone 
marrow biopsies and peripheral smears was undertaken 
before splenectomy.
The indications for splenectomy were primary rer
fractory ITP or relapsing refractory ITP that failed 
the firstrline therapy (steroids/intravenous immunor
globulin [IVIG]) or needed unacceptably high doses of 
steroids to maintain a safe platelet count and prevent 
bleeding, failed highrdose steroids for 2 weeks with a 
platelet count of 10×103/µL or less. Also included were 
patients who were bleeding with a fluctuating plater
let count above 10×103/µL but below 30×103/µL . 
Primary treatment was steroids at 1 mg/kg/day unless 
otherwise specified. None received monoclonal antir
body therapy (rituximab). Platelet transfusion was alr
lowed immediately before or during the procedure in 
patients with a platelet count <30×103/µL for laparor
scopic and <10×103/µL for open splenectomy in the 
absence of bleeding. For those who were taking prednir
sone before surgery, a switch to hydrocortisone during 
surgery at the dose of 50 mg IV every 6r8 hours was 
usually practiced until the patient was able to tolerate 
oral intake. Of the 28 OS patients, 26 had elective open 
splenectomy; two patients an underwent emergency 
procedure due to failure of steroid therapy and IVIG 
primary treatment and multiple salvage lines of therapy 
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(vincristine, highrdose pulse steroids, danazol, repeated 
IVIG) with a bleeding tendency. The laparoscopic spler
nectomy was performed as described elsewhere18 with 
the patient in a left semirdecubitus position under genr
eral anesthesia. Open splenectomy was done according 
to the international standard through a left subcostal or 
midline incision. For postrsplenectomy response, outr
come was assessed according to the criteria proposed by 
George et al.19
Diagnosis of VTE depended on clinical as well as 
radiological assessment with spiral CT of the chest 
(pulmonary embolism [PE] study), echocardiogram, 
electrocardiogram, and Doppler US of the lower limbs 
on the abdominopelvic veins. In those with PE, Doppler 
US of the hepatosplenic bed and inferior vena cava were 
also done. Drdimers level was introduced lately (2004) 
as part of VTE work up, but was not essential.
Statistical analysis was carried out using the Statr
View 4.5 and Prism 3.0 software. A twortailed P value 
equal to or less than .05 was considered statistically 
significant (t test). KaplanrMeier curves were used to 
estimate the cumulative rate of VTE in the first 30 days 
postsplenectomy. The average duration of stay postspler
nectomy was calculated from the time of anesthesia unr
til the time of discharge.
RESULTS
A total of 49 consecutive adult patients (14 males, 35 
females) with ITP underwent splenectomy (21 lapar
roscopic and 28 open) by the same teams and at the 
same units in 2 hospitals between 1995 and 2004 
(Table 1). None received prophylactic anticoagulants 
or antiplatelet agents. There were no deaths in either 
group. No cases of accessory spleens were detected inr
traoperatively or with follow up of relapsed cases. The 
median (range) age of the LS group (31 [18.9] years) 
was younger than the OS group (38 [17.7] years) with 
nearly the same duration of disease. The LS group had 
a higher mean platelet count (48×103/µL ) before the 
procedure compared to the OS group (18×103/µL) 
(P=.028).
Two (9.5%) of the 21 LS patients had clinically manr
ifested acute PE (one also had iliofemoral thrombosis); 
both occurred within the first week of splenectomy. 
The platelet count of the two patients reached a milr
lion within 7 days and 500 ×103/µL within 4 days after 
surgery. Three conversions to OS occurred; none had 
VTE. Postoperative recovery time was not prolonged 
in the VTE patients and no immobilization was rer
ported. None of the VTE patients had any infections. 
In OS group, DVT occurred in one patient at a plater
let count of 380×103/µL on the fifth postoperative day, 





   Median age in years (range) 31 (17-52) 38 (15-58)
   Female 17 (81) 18 (64)
   duration of iTp in months (range) 17.5 (6.5-42) 14 (1.5-57)
   primary  refractory 3 (14) 6 (21)
   relapsing refractory* 11 (52) 16 (57)
   iVig use before** surgery 6 (29) 4 (14)
   platelet rise to >40 k before surgerya 16 (76) 13 (46)
   Mean platelet count on day   
   splenectomyb (×103/µl) (range) 48 (11-227) 18 (<10-314)
   Vaccination before splenectomyc 16 (62) 11 (39)
   Mean hemoglobin (g/dl) (range) 12.3 (9.1-15.7) 13.1 (8.7-16.5)
   intra-operative platelet transfusion 4 (19) 6 (21)
   intra-operative blood transfusion  none 2 (7.1)
   post-operative platelet  transfusion 4 (19) 4 (14)
   pos-operative blood transfusion 2 (10) 5 (18)
   postoperative  other complications
      Wound infection 1 (5) 2 (7)
      Sub-phrenic abscess 1 (5) 1 (4) 
      Bleeding 2 (10) 2 (7)
   Conversion to open surgery 3 (14) ---
   Mean operative time (minutes) 175 (140-230) 185 (110-210)
   anticoagulant prophylaxis none (0) none (0)
Values are n(%) unless otherwise indicated. aP= .07, bP= .037, cP= .015.
one at a platelet count of 120×103/µL on the eleventh 
day, and a third at a platelet count of 150×103/µL on 
the thirteenth day . There was no significant difference 
in estimated blood loss, lengthrofrstay, or time to oral 
intake between the two groups. The mean (SD) durar
tion of stay was 4.8 (2.9) days for LS and 3.7 (2.1) days 
for OS (P=.04).
Complications
Two of the 21 (9.5%) patients in the LS group develr
oped clinically manifest acute pulmonary embolism 
(one also had iliofemoral thrombosis); both occurred 
within 5 days of LS and their platelet count reached 
500×103/µL within 4 days and a million within 7 days. 
Moreover, they also had the lowest baseline platelet count 
(<10×103/µL) before LS for more than 3 weeks with 
failure to respond to steroids and IVIG. Three converr
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sions to OS occurred; none had VTE. One was a single 
female aged 34 years was found to have PE at a plater
let count of 520×103/µL on the fourth day. However, 
she reported painful left lower limb swelling the night 
before. This necessitated extension of admission and 
systemic anticoagulation. She also bled postoperatively 
and required 2 units of packed red cell transfusion, but 
no revision or rerexploration was needed; the patient 
remained in hospital for 7 days. Within 2 weeks, the 
platelet count rebounded to 1050×103/µL and she was 
treated and maintained on hydroxyurea for 6 months 
to keep the platelet count within 600×103/µL . After 
6 months she developed progressive hypereosinophilia 
(eosinophils 4500/ µL) with a fluctuation of platelet 
count between 55×103/µL to 780×103/µL followed by 
a constellation of clinicopathologic findings of primary 
hypereosinophilic syndrome. Cytogenetic studies of the 
bone marrow did not disclose an abnormal cytogenetic 
pattern. Molecular testing for BCR/ABL was negar
tive. The second patient was a 29ryearrold female who 
was also 12 months postpartum and lactating. She had 
persistent pain after surgery and incompletely opened 
her bowel before discharge with a marked decrease in 
her oral fluid intake due to the persistent pain at the 
site of the laparoscope. She was discharged on the third 
day 43 hours postsplenectomy. The platelet count was 
110×103/µL on the second day, 270×103/µL on the 
third day and 570×103/µL on the fourth day. No unr
derlying disease was found at the 4ryear follow up.
In the OS group, systemic VTE in the form of DVT 
occurred in 3 patients (11%). None were life threatenr
ing. One patient had unilateral iliofemoral DVT within 
5 days of OS at a platelet count of 300×103/µL and 
two had popliteal DVT at a platelet count of 150×103/
µL and 120×103/µL ; the later developed clinical lupus 
with nephritic syndrome a year later. None of the cases 
showed a rapid rise of the platelet count more than 
300×103/µL over a week. Both the first and the second 
patients were also cushingoid with significant obesity 
(>25% increase in body mass index) and the second one 
had IVIG presplenectomy in preparation for splenecr
tomy. Due to skin thickness and obesity, they stayed in 
the hospital longer than other patients. Other complir
cations were wound infection (n=20), subphrenic abr
scess (n=1) and bleeding (n=3). No accessory spleens 
were detected.
DISCUSSION
The occurrence of VTE in the immediate (within 1 
month) postsplenectomy period (laparoscopic and open) 
in our study with such a significant incidence (9.5% and 
10.7%, respectively) in the absence of anticoagulant 
prophylaxis indicates clearly that the postsplenectomy 
period is an acquired “thrombophilic condition” even if 
the underlying disease for which splenectomy is done is 
a bleeding one. Clearly any surgery heightens the risk of 
thrombosis to a wide degree depending on various adr
ditional risk factors. It is reported to be higher in the elr
derly undergoing prolonged splenectomy for malignant 
hematological conditions and is expected to be much 
lower with younger age and with the laparoscopic apr
proach in apparently normal and small spleen patients, 
as in ITP. The proposed mechanisms of thrombosis 
in such cases include thrombocytosis, leukocytosis, 
dehydration, subclinical or overt infections, prolonged 
recumbence, and local injury of the tail of the pancreas 
or even very prolonged surgery alone.8 Postsplenectomy 
thrombocytosis may reach a 1000×103/µL in some par
tients and predispose to thrombosis locally at the portal 
or mesenteric veins or distally and systemically in the 
form of DVT and/or PE. The association between 
postsplenectomy thrombocytosis and VTE is unclear, 
particularly in ITP patients since not all patients with 
thrombocytosis develop VTE and VTE occurred in 
some patients without thrombocytosis.20,21 A relatively 
recent study investigating the etiology and clinical sigr
nificance of thrombosis found a higher incidence of ver
nous and arterial thrombosis in patients with primary 
as compared to secondary thrombocytosis (12.4% vs. 
1.6%). The authors conclude that postsplenectomy 
Table 2. Systemic thromboembolic complications post-splenectomy (n=49).
   Feature Laparoscopic splenectomy (n=21)
Open 
splenectomy (n=28)
   VTe
   life threatening 2 (9.52) none
   not life threatening none 3 (10.7%)
   Time to manifest VTe 5 days, 4 days 5, 11, 13 days
   Secondary disease 1 case progressed to HeS 1 case Sle
   Time to manifest underlying   
   secondary disease 6 months (1 patient) 11 months (1 patient)
   presentation 
      place 
      Onset and clinical 
      presentation  
inpatient (n=1), at home 
(n=1), sudden SOB (n=2), 
dizziness for several 
hours then shock, acute 
respiratory failure
all with relatively 
slower rate over a few 
days, swelling,
pain (n=3), and low 
grade temp (n=1)
   age (y) of VTe cases  34, 29 30, 24 and  42
   Sex of  VTe cases (F/M) 2/0 2/1
   Mortality none none
Values are n(%) unless otherwise indicated. HeS: hypereosinophilic syndrome. SOB: shortness of breath.
original research reportlaparOSCOpiC SpleneCTOMY
Hematol Oncol Stem Cell Ther 3(2)     Second Quarter 2010 hemoncstem.edmgr.com 75
thrombocytosis is not associated with an increased risk 
of thrombosis.22 However, the clinical features and perir
operative prophylaxis were not detailed in the study. 
Rapidly recovering platelet count in the midst of prer
operative status of an uprregulated coagulation cascade 
and cytoadhesion molecules on both platelet membrane 
and endothelial cells before surgery with an exponential 
increase of platelet count with surgery seems a plausible 
explanation for thrombosis that may occur even in the 
absence of thrombocytosis.23 However, there are no data 
correlating the rapidity of recovery and overshooting of 
the platelet count and the incidence of thrombosis, esr
pecially DVT and PE, probably because the number of 
patients developing such a complication is still low and 
the data on LS in such patients is scarce.12 The additionr
al impact of an increased white cell count has not been 
studied and is difficult to interpret from the available 
reports, although it may be operational but it has been 
described before in relation to the myeloproliferative 
diseases, mainly polycythemia vera and sickle cell disr
eases with autosplenectomy.24 Fontana et al25 reported 
increased procoagulant cellrderived microparticles (Cr
MP) in splenectomized patients. The levels of all the 
cellular microparticles from red cells, white cells, and 
endothelial cells increase in ITP patients after splenecr
tomy whether this is laparoscopic or open. Interestingly, 
increased red cell CrMP was linearly correlated to and 
associated with shortened activated partial thrombor
plastin time (APTT) and increased activity of the cor
agulation factors VIII (P=.023), IX (P=.021) and XI 
(P=. 009).
Splenectomy itself as a surgery—whatever the apr
proach—represents a thrombogenic stress, but it is not 
usually associated with high risk for thrombotic comr
plication unless other significant other risk factors are 
also operational. An extremely low incidence of VTE 
has been reported by a large French study of 275 lapar
roscopic splenectomies for patients with various hemar
tological disorders, including ITP (1 %).7 Only 1 of 12 
patients with ITP developed portal vein thrombosis 
(PVT) without any further systemic thrombosis in 
an Italian study.26 Such a small number may be diffir
cult to evaluate particularly in absence of a comparative 
group. Cordera et al,5 reported the same very low rate of 
thrombosis in 1 of 42 laparoscopic and in 2 of 44 open 
splenectomies without delineating the sites of VTE. 
Vianelli et al27 alluded to the relatively better technir
cal and postoperative outcomes—including thrombor
embolic complications in patients with ITP who unr
derwent LS compared to those with other malignant 
hematological disorders. However, the rate of systemic 
VTE was extremely low in ITP patients in their study. 
Similarly, Zamir et al28 reported no single VTE event 
in any of his 17 patients who underwent LS; 15 were 
ITP. Tanoue et al29 reported on 41 ITP patients who 
underwent LS and 64 OS, but did not mention postopr
erative VTE in either group probably because most of 
the follow up of these patients had been with their relr
evant hematology service; therefore many of cases could 
have been missed. This highlights the paucity of data 
on paradoxical thrombosis in such a bleeding disorder. 
Although the total number of patients is small, Lozanor
Salazar et al30 reported PE in 1 of 6 patients who unr
derwent LS while none of the other 10 patients who 
underwent OS manifested any reportable VTE. No 
details pertinent to that patient were added. Schlinkert 
and Mann31 reported on 21 ITP patients (17 underr
went open and 7 laparoscopic splenectomies) and none 
in the LS group developed VTE, but as mentioned by 
the authors, this may have been due to patient selection. 
Svensson et al32 reported a total of 7 patients who develr
oped thromboembolic complications out of 69 patients 
who underwent splenectomy (39 LS and 30 OS) for 
various hematological disorders, including malignant 
hematological disorders (37 patients), hypersplenr
ism, hemolytic anemia and ITP. The overall incidence 
of VTE was 7 out of 69 (10%) in spite of the use of 
shortrcourse prophylactic anticoagulants in those with 
malignant hematologic disorders. Surprisingly, the only 
two patients who developed lower limb DVT belonged 
to the ITP patients who underwent laparoscopic spler
nectomy, but they did not receive thromboembolic 
prophylaxis as did those with malignant disorders. The 
remaining 5 cases of VTE occurred in those with mar
lignant disorders were localized to the portal vein. No 
clear explanation was discussed by the authors regardr
ing the contributing factors to DVT in the ITP group. 
Although there is another possibility that silent DVT 
may be present before surgery, this looks unusual and 
remote with true isolated ITP patients. Mastrojeni et 
al33 indicated that DVT and pulmonary embolism are 
the dangerous and serious complications in patients 
who underwent pneumoperitoneum with CO2 durr
ing laparoscopic abdominal surgery. The authors sugr
gested that modern diagnostic tools can make it posr
sible to identify preoperatively relatively silent clinical 
thrombosis, which can also be detected with laboratory 
tests (i.e., Drdimer plasma levels) and stressed the imr
portance of a careful preoperative evaluation of the ver
nous system, by Doppler study, to identify patients at 
risk of DVT and establish a suitable antirthrombotic 
prophylaxis. The patient who developed DVT and PE 
and then hypereosinophilic syndrome (HES) may have 
possibly been harboring a silent DVT before laparor
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scopic splenectomy due to her underlying prerclinical 
HES. Malignant hematological disorders, especially 
myeloproliferative neoplasias, are associated with a 
significantly higher rate of thromboembolic complicar
tions in the extremities as well as in the visceral veins. 
Nevertheless, thromboembolic complications may 
predate the overt appearance of the disease.34 Further 
evaluation and stratification of the risk of thrombosis 
is required as the risk varies with time and with recovr
ery of the platelet count. There is little evidence that 
the method of splenectomy (open vs. laparoscopic) has 
an impact on subsequent thromboembolic complicar
tions.8 The effect of splenectomy on accelerating the 
overt manifestation of an underlying disease (HES in 
LS and SLE in OS) cannot be completely excluded as 
in the case with HES who manifested her overt clinical 
features of the disease a few months after splenectomy 
with hypereosinophilia, pulmonary involvement and 
eosinophilic gastritis. Surprisingly, her platelet count 
fluctuated widely with two episodes of relapses of her 
thrombocytopenia off steroids with a rebound to over 
a million on intermediate doses of steroids and normalr
ization of platelets at low intermittent doses (20 mg evr
ery other day). The same may also hold true for the SLE 
patient who presented 11 months later with nephritic 
syndrome and antiphospholipid antibody syndrome 
that proved to be lupus in origin, although his plater
let count remained within the normal range at the time 
of presentation with frequent fluctuation and frequent 
relapses of his autoimmune thrombocytopenia over 2 
years at the last follow up. The significant rate of thromr
bosis and the liferthreatening nature of the presentation 
does not seem to relate to the cumulative experience of 
the center or the personnel12 because cases of PE and/
or extensive DVT were late comers who had splenecr
tomy after 8 to 9 years of cumulative experience at both 
institutes. In addition, ITP spleens are relatively norr
mal in size, representing the “ideal” spleens for removal 
by laparoscopy. Moreover, such serious VTEs do not 
seem to relate to the technical outcome of the procer
dure (operative time, intraoperative details, conversion 
and postoperative pain), but to the systemic acquired 
thrombophilic status that is heightened after splenecr
tomy and may also be related to the underlying disease 
of HES that manifested later. Because all patients who 
developed DVT were relatively young and the splenecr
tomy procedure is a relatively short procedure, other 
operational factors like hereditary thrombophilic conr
ditions factor V Leiden mutation, prothrombin mutar
tion and coagulation factor inhibitor deficiency (protein 
C and Protein C and ATIII) should also be sought as it 
is known that such abnormalities are relatively not unr
common among whites.35 Hypothetically, laparoscopic 
splenectomy may have given the patients and the care 
givers a false sense of safety after the procedure that 
may explain the life threatening or extensive nature of 
the VTE at the time of presentation.
In conclusion, ITP patients are not immune from 
developing PE and or DVT after splenectomy whether 
open or laparoscopic. Patients at risk are those who 
have an exponential rise of the platelet count. It may 
occur even after discharge at home and extra caution 
should be undertaken for proper prophylaxis and manr
agement to avoid such liferthreatening situations. We 
should not differentiate between laparoscopic vs. open 
splenectomy when formulating anticoagulant indicar
tions. Consideration of additional risk factors should be 
factored into the management plan to optimally prevent 
the occurrence of such complications. Close monitorr
ing of platelet count should be considered. Nonetheless, 
early mobilization good hydration and starting prophyr
lactic anticoagulants at an early period of time once 
hemostasis is systemically and locally secured should 
be practiced. Prophylaxis with antiplatelet agents such 
as aspirin needs further study in cases with extreme 
thrombocytosis (1 million/µL)as it is not expected to 
be associated with bleeding tendencies as compared to 
cases of essential thrombocythemia.36
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